2025 was a groundbreaking year for cardiovascular medicine, challenging long-standing practices and sparking debates among experts. But what exactly happened, and why should you care?
Aspirin's Demise: The year started with a bang as new research questioned the routine use of aspirin for cardiovascular health. The Medical Republic reported that studies found no significant benefits, while risks were substantially increased. This led to a reevaluation of lifelong aspirin prescriptions, with superior alternatives like clopidogrel taking center stage. A clinical trial even had to be stopped early due to excess deaths, a stark reminder of the evolving nature of medical knowledge. But here's where it gets controversial—should we be quick to dismiss a long-trusted medication, or is there more to the story?
Combination Therapies Take Center Stage: The push for single pill combinations (SPCs) and fixed dose combinations (FDCs) as first-line hypertension treatments gained momentum in 2025. Despite urgent calls for PBS updates, changes have yet to be implemented. This delay raises questions about the pace of healthcare policy adjustments and their impact on patient care.
CRISPR's Promise: Australian researchers made history with the first successful in-human trial using CRISPR gene-editing to manage cholesterol. This breakthrough offers a new approach to treating mixed lipid disorders. Imagine a single injection that tackles multiple issues—a potential game-changer!
Dyslipidaemia Management Revolution: The European Society of Cardiology and the European Atherosclerosis Society released bold new recommendations for dyslipidaemia management. They advocated for a more aggressive approach, moving away from traditional slow-and-steady tactics. The guidelines emphasized the importance of Lp(a) testing, a previously overlooked risk factor, which could prevent numerous heart attacks and strokes. But is this shift towards more intensive treatment universally beneficial, or might it lead to over-medicalization?
PCSK9 Inhibitors in the Spotlight: The American Heart Association's scientific sessions featured multiple studies on PCSK9 inhibitors for cholesterol management. One study found that combining these inhibitors with statins provided even greater protection against cardiovascular events. But with great power comes great responsibility—how do we ensure these treatments are accessible and affordable for all who need them?
In summary, 2025 was a year of significant progress and controversy in cardiology. From aspirin's fall from grace to the rise of gene-editing, these developments will shape the future of cardiovascular care. As we move forward, it's essential to stay informed, question assumptions, and engage in open discussions about the best ways to protect our hearts and health. What do you think? Are these changes long overdue, or should we proceed with caution?
